News

The research collaboration will build on the company’s manufacturing protocol for its lead cancer program, CLBS20 (NBS20). All the parties will explore new techniques to further improve the

The Phase II Pathway Study’s primary efficacy outcome is the change in motor strength of the various muscle groups in the upper extremities innervated by the cervical spinal

The breakthrough therapy designation follows positive results from ARC001, which is the company’s randomized, double-blind, placebo-controlled Phase II trial of AR101 for desensitization treatment of peanut allergy. At

Glatopa is the first AP-rated substitutable generic designed to treat patients with relapsing-forms of multiple sclerosis (RRMS), a chronic disease of the central nervous system characterized by inflammation

The company said that the time frame for FDA review is about 30 days. CLI is caused by reduced blood flow to the legs and about half of

The trial is designed to assess the role of edoxaban in VTE patients associated with cancer (other than basal-cell or squamous-cell carcinoma of the skin) for whom long-term

The collaboration, which was facilitated by the Johnson & Johnson Innovation Center in Boston, utilizes Emulate’s Organs-on-Chips to advance the clinical goals for three Janssen R&D programs at

Topline results from this study are now expected in Q1 2016. GPR84 was identified as a target for these diseases through Galapagos’ target discovery platform and GLPG1205 is

In the clinical program, statistically significant differences in muscle strength as compared to a matched external control cohort and a favorable safety profile were observed. "We are excited